Siglec-7 Antibody (H-2): sc-398166
- Siglec-7 Antibody (H-2) is a mouse monoclonal IgG2b κ provided at 200 µg/ml
- raised against amino acids 407-454 mapping near the C-terminus of Siglec-7 of human origin
- recommended for detection of Siglec-7 of human origin by WB, IP, IF and ELISA
- m-IgG2b BP-HRP and m-IgGκ BP-HRP are the preferred secondary detection reagents for Siglec-7 Antibody (H-2) for WB applications. These reagents are now offered in bundles with Siglec-7 Antibody (H-2) (see ordering information below).
Siglec-7 Antibody (H-2) is a mouse monoclonal IgG2b antibody that detects Siglec-7 in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Siglec-7 plays a crucial role in the immune system, particularly in modulating the activity of natural killer (NK) cells, which are essential for the body′s defense against tumors and viral infections. By binding to sialylated ligands on target cells, Siglec-7 inhibits NK cell cytotoxicity, thereby regulating immune responses and maintaining homeostasis. This regulatory function is vital, as Siglec-7 helps prevent excessive immune reactions that could lead to tissue damage or autoimmune diseases. Siglec-7 expression is predominantly found in monocytes and resident blood cells, highlighting Siglec-7′s importance in immune cell interactions and signaling. The ability of Siglec-7 to mediate these interactions underscores Siglec-7′s potential as a therapeutic target in diseases where immune modulation is beneficial. With specificity for human samples and versatility in various applications, anti-Siglec-7 antibody (H-2) serves as an invaluable tool for researchers studying immune regulation and cell signaling pathways.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
Siglec-7 Antibody (H-2) References:
- Siglec-7 on peripheral blood eosinophils: Surface expression and function. | Legrand, F., et al. 2019. Allergy. 74: 1257-1265. PMID: 30690753
- NK Cell-Based Immune Checkpoint Inhibition. | Khan, M., et al. 2020. Front Immunol. 11: 167. PMID: 32117298
- Siglec-7 is a predictive biomarker for the efficacy of cancer vaccination against metastatic colorectal cancer. | Yamada, K., et al. 2021. Oncol Lett. 21: 10. PMID: 33240416
- Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9. | Rodriguez, E., et al. 2021. Nat Commun. 12: 1270. PMID: 33627655
- Siglec-7 May Limit Natural Killer Cell-mediated Antitumor responses in Bladder Cancer Patients. | Benmerzoug, S., et al. 2021. Eur Urol Open Sci. 34: 79-82. PMID: 34825225
- Siglec-7 represents a glyco-immune checkpoint for non-exhausted effector memory CD8+ T cells with high functional and metabolic capacities. | Haas, Q., et al. 2022. Front Immunol. 13: 996746. PMID: 36211376
- Siglec-7 glyco-immune binding mAbs or NK cell engager biologics induce potent antitumor immunity against ovarian cancers. | Bordoloi, D., et al. 2023. Sci Adv. 9: eadh4379. PMID: 37910620
- The glycoimmune checkpoint receptor Siglec-7 interacts with T-cell ligands and regulates T-cell activation. | Stewart, N., et al. 2024. J Biol Chem. 300: 105579. PMID: 38141764
- Targeting myeloid cells for cancer immunotherapy: Siglec-7/9/10/15 and their ligands. | Boelaars, K. and van Kooyk, Y. 2024. Trends Cancer. 10: 230-241. PMID: 38160071
- Increased Siglec-9/Siglec-9L interactions on NK cells predict poor HCC prognosis and present a targetable checkpoint for immunotherapy. | Xiao, R., et al. 2024. J Hepatol. 80: 792-804. PMID: 38331327
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Siglec-7 Antibody (H-2) | sc-398166 | 200 µg/ml | $322.00 | |||
Siglec-7 Antibody (H-2): m-IgGκ BP-HRP Bundle | sc-535987 | 200 µg Ab; 40 µg BP | $361.00 | |||
Siglec-7 Antibody (H-2): m-IgG2b BP-HRP Bundle | sc-549500 | 200 µg Ab; 10 µg BP | $361.00 |